Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming

With over 60,000 cases diagnosed in women annually, ductal carcinoma in situ (DCIS) is the most common form of pre-invasive breast cancer in the US. Despite standardized therapy, under-treatment and over-treatment are prevailing concerns. By understanding the mechanisms regulating DCIS progression,...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Fang, Yuuka Kozai, Diana S. Acevedo, Rebecca Brodine, Haasini S. Gorrepati, Nizhoni Arviso, Paige Cote, Alala Thompson, Zachary Gerdes, Ashley Espinoza, Nick Bergeron, Audrey Brownfield, Nikki Cheng
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Cancer Biology & Therapy
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/15384047.2025.2535824
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850068567400120320
author Wei Fang
Yuuka Kozai
Diana S. Acevedo
Rebecca Brodine
Haasini S. Gorrepati
Nizhoni Arviso
Paige Cote
Alala Thompson
Zachary Gerdes
Ashley Espinoza
Nick Bergeron
Audrey Brownfield
Nikki Cheng
author_facet Wei Fang
Yuuka Kozai
Diana S. Acevedo
Rebecca Brodine
Haasini S. Gorrepati
Nizhoni Arviso
Paige Cote
Alala Thompson
Zachary Gerdes
Ashley Espinoza
Nick Bergeron
Audrey Brownfield
Nikki Cheng
author_sort Wei Fang
collection DOAJ
description With over 60,000 cases diagnosed in women annually, ductal carcinoma in situ (DCIS) is the most common form of pre-invasive breast cancer in the US. Despite standardized therapy, under-treatment and over-treatment are prevailing concerns. By understanding the mechanisms regulating DCIS progression, we may develop tailored strategies to improve treatment. CCL2/CCR2 and HGF/MET signaling pathways are upregulated in breast cancers. Our studies indicate that these pathways cooperate to promote DCIS progression and metabolism. DCIS and IDC tissues were immunostained for CCL2 and HGF expression. DCIS.com and HCC1937 cells were analyzed for cell proliferation through PCNA immunostaining, apoptosis through cleaved caspase-3 immunostaining, and invasion through Matrigel transwell assays. AKT, AMPK, p42/44MAPK and PKC activities were analyzed in vitro through immunoblot and pharmacologic inhibition. CCL2 and HGF-mediated metabolism were analyzed by LC-MS. Glucose uptake and lactate production were measured biochemically. CCR2 and MET were targeted in breast xenografts through CCR2 knockout and treatment with Merestinib. Significant associations between CCL2 and HGF were detected in DCIS and IDC tissues. CCL2 and HGF co-treatment enhanced breast cancer cell growth, survival, and invasiveness over individual CCL2 or HGF treatment. These CCL2/HGF-mediated phenotypes were associated with metabolic changes including glycolysis and increased AKT, AMPK, p42/44MAPK and PKC signaling. CCL2/HGF-mediated glycolysis was reduced with AKT, AMPK and p42/44MAPK inhibition. CCR2 knockout combined with Merestinib treatment inhibited growth, survival, and stromal reactivity of breast xenografts more than CCR2 or MET targeting alone. CCL2/CCR2 and HGF/MET cooperate to enhance breast cancer progression and metabolic reprogramming.
format Article
id doaj-art-c3c475a8559e496abf4c2cb03463a985
institution DOAJ
issn 1538-4047
1555-8576
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Cancer Biology & Therapy
spelling doaj-art-c3c475a8559e496abf4c2cb03463a9852025-08-20T02:48:01ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762025-12-0126110.1080/15384047.2025.2535824Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogrammingWei Fang0Yuuka Kozai1Diana S. Acevedo2Rebecca Brodine3Haasini S. Gorrepati4Nizhoni Arviso5Paige Cote6Alala Thompson7Zachary Gerdes8Ashley Espinoza9Nick Bergeron10Audrey Brownfield11Nikki Cheng12Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USADepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USAWith over 60,000 cases diagnosed in women annually, ductal carcinoma in situ (DCIS) is the most common form of pre-invasive breast cancer in the US. Despite standardized therapy, under-treatment and over-treatment are prevailing concerns. By understanding the mechanisms regulating DCIS progression, we may develop tailored strategies to improve treatment. CCL2/CCR2 and HGF/MET signaling pathways are upregulated in breast cancers. Our studies indicate that these pathways cooperate to promote DCIS progression and metabolism. DCIS and IDC tissues were immunostained for CCL2 and HGF expression. DCIS.com and HCC1937 cells were analyzed for cell proliferation through PCNA immunostaining, apoptosis through cleaved caspase-3 immunostaining, and invasion through Matrigel transwell assays. AKT, AMPK, p42/44MAPK and PKC activities were analyzed in vitro through immunoblot and pharmacologic inhibition. CCL2 and HGF-mediated metabolism were analyzed by LC-MS. Glucose uptake and lactate production were measured biochemically. CCR2 and MET were targeted in breast xenografts through CCR2 knockout and treatment with Merestinib. Significant associations between CCL2 and HGF were detected in DCIS and IDC tissues. CCL2 and HGF co-treatment enhanced breast cancer cell growth, survival, and invasiveness over individual CCL2 or HGF treatment. These CCL2/HGF-mediated phenotypes were associated with metabolic changes including glycolysis and increased AKT, AMPK, p42/44MAPK and PKC signaling. CCL2/HGF-mediated glycolysis was reduced with AKT, AMPK and p42/44MAPK inhibition. CCR2 knockout combined with Merestinib treatment inhibited growth, survival, and stromal reactivity of breast xenografts more than CCR2 or MET targeting alone. CCL2/CCR2 and HGF/MET cooperate to enhance breast cancer progression and metabolic reprogramming.https://www.tandfonline.com/doi/10.1080/15384047.2025.2535824CCL2HGFchemokineCCR2METmetabolism
spellingShingle Wei Fang
Yuuka Kozai
Diana S. Acevedo
Rebecca Brodine
Haasini S. Gorrepati
Nizhoni Arviso
Paige Cote
Alala Thompson
Zachary Gerdes
Ashley Espinoza
Nick Bergeron
Audrey Brownfield
Nikki Cheng
Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
Cancer Biology & Therapy
CCL2
HGF
chemokine
CCR2
MET
metabolism
title Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
title_full Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
title_fullStr Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
title_full_unstemmed Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
title_short Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
title_sort cooperative ccl2 ccr2 and hgf met signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
topic CCL2
HGF
chemokine
CCR2
MET
metabolism
url https://www.tandfonline.com/doi/10.1080/15384047.2025.2535824
work_keys_str_mv AT weifang cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT yuukakozai cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT dianasacevedo cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT rebeccabrodine cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT haasinisgorrepati cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT nizhoniarviso cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT paigecote cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT alalathompson cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT zacharygerdes cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT ashleyespinoza cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT nickbergeron cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT audreybrownfield cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming
AT nikkicheng cooperativeccl2ccr2andhgfmetsignalingenhancesbreastcancergrowthandinvasionassociatedwithmetabolicreprogramming